Publications by authors named "J Vial"
Corrosion inhibitors (CIs) are extensively employed in the oil and gas industry, yet their analysis remains a challenge. To develop a suitable liquid chromatography method for a wide array of CIs, a column screening was conducted. Nine different chromatographic conditions were tested across eight RPLC and mixed-mode columns (Accucore C18, CORTECS Shield RP18, Acquity HSS T3, Acquity Premier HSS T3, Accucore 150-C4, Accucore PFP, Synergi Polar RP, and Acclaim WCX-1).
View Article and Find Full Text PDFAccording to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared the efficacy of mini-consolidations (idarubicin 8 mg/m day 1, cytarabine 50 mg/m/12 h, day 1-5) and IDAC.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the importance of characterizing renewable gases, particularly focusing on trace volatile organic compounds (VOCs) that could affect the gas chain at low concentrations.
- It emphasizes the critical role of proper sampling methods in analyzing these trace VOCs and investigates various factors, such as stabilization time and external temperatures, that could affect sampling accuracy.
- The findings reveal that a 45-minute stabilization is necessary for reliable results, external temperature only minimally affects the results, and using an intermediate sampling cylinder can lead to a loss of compounds if not handled properly.
Article Synopsis
- The study examines the effectiveness and complications of Finney and Jaboulay pyloroplasties used to treat non-cancerous gastric outlet issues in dogs and cats from January 2015 to August 2023.
- A total of 13 pets (8 dogs and 5 cats) underwent these surgeries for various gastric conditions, with treatments resulting in no major complications.
- Follow-up showed excellent outcomes for all cases, with no reported clinical signs or need for further medical treatment, indicating these surgical methods are both safe and effective.
Article Synopsis
- Acute myeloid leukemia (AML) with BCR::ABL1 is classified as an adverse-risk group in the 2022 ELN classification, but its outcomes with modern treatment options like tyrosine kinase inhibitors are not well understood.
- In a study of 20 patients with de novo BCR::ABL1 AML from a large registry, most received standard chemotherapy with imatinib, leading to a high complete remission rate of 94.4%.
- The survival rates suggest BCR::ABL1 AML patients have better outcomes than those classified in traditional adverse-risk categories, indicating they may need reclassification in future treatment guidelines.